Answers are grounded in this paper and cite their sources.
In vitro assays report a new TDC's efficacy against ovarian cancer, implying a breakthrough in treatment strategies.
By applying our pioneering "Targeted Drug Conjugate (TDC)" concept, a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported. In vitro biological assays indicated that the representative compound Ola-604 could target PARP1, exhibit an inhibitory effect on SKOV3 cancer cells, and overcome cisplatin resistance via inducing cell apoptosis, causing cell cycle arrest, enhancing the cellular accumulation of platinum element, promoting the level of DNA platination within the genome, and suppressing DNA damage repair. Notably, compound Ola-604 demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: